Withhold fluorouracil for any of the following:
• Development of angina, myocardial infarction/ischemia, arrhythmia, or heart failure
in patients with no history of coronary artery disease or myocardial dysfunction
[see Warnings and Precautions (
5.2)]
• Hyperammonemic encephalopathy [see Warnings and Precautions (
5.3)]
• Acute cerebellar syndrome, confusion, disorientation, ataxia, or visual disturbances
[see Warnings and Precautions (
5.4)]
• Grade 3 or 4 diarrhea [see Warnings and Precautions (
5.5)]
• Grade 2 or 3 palmar-plantar erythrodysesthesia (hand-foot syndrome) [see Warnings and
Precautions (
5.6)]
• Grade 3 or 4 mucositis [see Warnings and Precautions (
5.8)]
• Grade 4 myelosuppression [see Warnings and Precautions (
5.7)]
Upon resolution or improvement to Grade 1 diarrhea, mucositis, myelosuppression, or palmarplantar erythrodysesthesia, resume fluorouracil administration at a reduced dose. There is no recommended dose for resumption of fluorouracil administration following development of any of the following adverse reactions:
• Cardiac toxicity
• Hyperammonemic encephalopathy
• Acute cerebellar syndrome, confusion, disorientation, ataxia, or visual disturbances